Azzad Asset Management Inc. ADV bought a new stake in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 21,077 shares of the biotechnology company's stock, valued at approximately $2,682,000.
A number of other institutional investors have also recently modified their holdings of RGEN. Signaturefd LLC boosted its holdings in Repligen by 172.2% in the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock worth $28,000 after buying an additional 124 shares during the last quarter. Sava Infond d.o.o. acquired a new stake in Repligen in the 4th quarter worth about $29,000. Raiffeisen Bank International AG acquired a new stake in Repligen in the 4th quarter worth about $29,000. Itau Unibanco Holding S.A. acquired a new stake in Repligen in the 4th quarter worth about $40,000. Finally, Global Retirement Partners LLC boosted its holdings in Repligen by 54.0% in the 4th quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company's stock worth $53,000 after buying an additional 129 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.
Repligen Trading Down 1.5%
Shares of RGEN stock traded down $1.78 during trading on Wednesday, hitting $119.23. 890,235 shares of the stock traded hands, compared to its average volume of 737,689. The firm has a market capitalization of $6.70 billion, a P/E ratio of -264.66, a price-to-earnings-growth ratio of 3.61 and a beta of 1.10. The company has a debt-to-equity ratio of 0.27, a current ratio of 6.79 and a quick ratio of 5.79. The firm's fifty day moving average price is $128.87 and its 200-day moving average price is $142.54. Repligen Corporation has a 52-week low of $102.97 and a 52-week high of $182.52.
Repligen (NASDAQ:RGEN - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, beating the consensus estimate of $0.35 by $0.04. Repligen had a negative net margin of 3.93% and a positive return on equity of 4.53%. The firm had revenue of $169.17 million during the quarter, compared to the consensus estimate of $163.65 million. During the same quarter last year, the firm earned $0.28 EPS. The firm's revenue for the quarter was up 10.4% on a year-over-year basis. As a group, research analysts forecast that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of research analysts have weighed in on RGEN shares. Wall Street Zen raised shares of Repligen from a "sell" rating to a "hold" rating in a research note on Thursday, May 8th. Evercore ISI started coverage on shares of Repligen in a research note on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 target price on the stock. Wolfe Research raised shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 target price on the stock in a research note on Tuesday, April 29th. Royal Bank Of Canada decreased their target price on shares of Repligen from $202.00 to $189.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 30th. Finally, Canaccord Genuity Group decreased their target price on shares of Repligen from $170.00 to $150.00 and set a "hold" rating on the stock in a research note on Wednesday, April 16th. Six analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $173.25.
Read Our Latest Stock Report on RGEN
About Repligen
(
Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Read More
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
